

Filed: April 26, 2019

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner,

v.

BIOGEN MA INC.,  
Patent Owner.

---

IPR2018-01403  
Patent No. 8,399,514

---

**PATENT OWNER'S NOTICE OF DEPOSITION OF  
JENNIFER ROCK**

Pursuant to 37 C.F.R. § 42.53, Patent Owner Biogen MA Inc., hereby provides notice that it will cross-examine Jennifer Rock, a witness of Petitioner Mylan Pharmaceuticals Inc. The cross-examination will begin at 3:00 p.m. CT on May 2, 2019 at the offices of Thomson Reuters, 610 Opperman Dr., Eagan, MN 55123. The parties have agreed on this date and time for the cross-examination of Jennifer Rock.

The cross-examination will be recorded by stenographic means by a court reporter licensed to administer oaths, and will also be recorded using audio and/or visual means.

Respectfully submitted,

Dated: April 26, 2019

By: /Barbara C. McCurdy/  
Barbara C. McCurdy, Reg. No. 32,120  
Mark J. Feldstein, Reg No. 46,693  
Erin M. Sommers, Reg. No. 60,974  
Pier D. DeRoo, Reg. No. 69,340  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP

**Counsel for Patent Owner  
Biogen MA Inc.**

**CERTIFICATE OF SERVICE**

The undersigned certifies that a copy of the foregoing Patent Owner Notice of Deposition was served electronically via e-mail on April 26, 2019, in its entirety on the following:

Brandon M. White  
Perkins Coie LLP  
700 13th St., NW, Suite 600  
Washington, D.C. 20005  
Telephone: (202) 654-6206  
E-mail: bmwhite@perkinscoie.com

David L. Anstaett  
Emily Greb  
Perkins Coie LLP  
One East Main St., Suite 201  
Madison, WI 53703  
Telephone: (608) 663-7494  
Email: danstaett@perkinscoie.com  
E-mail: egreb@perkinscoie.com

Petitioner has agreed to electronic service.

Dated: April 26, 2019

By: / Catherine A. Sadler /

Catherine A. Sadler  
Case Manager

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP